References
Anderson NL, Anderson NG (2002) The human plasma proteome. History, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867
Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A (2004) The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3:311–326
Asher DM (1999) Bovine sera used in the manufacture of biologicals: current concerns and policies of the US Food and Drug Administration regarding the transmissible spongiform encephalopathies. Dev Biol Stand 99:41–44
Bohn B (1995) Fatal bovine serum. Nat Biotechnol 13:926–927
Brunner D, Frank J, Appl H, Schöffl H, Pfaller W, Gstraunthaler G (2010) Serum-free cell culture: the serum-free media interactive online database. ALTEX 27:53–62
Dormont D (1999) Transmissible spongiform encephalopathy agents and animal sera. Dev Biol Stand 99:25–34
Even MS, Sandusky CB, Barnard ND (2006) Serum-free hybridoma culture: ethical, scientific and safety considerations. Trends Biotechnol 24:105–108
FDA (2013) US Food and Drug Administration; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?ID=117863
Fujimoto B (2002) Fetal bovine serum—supply vs. demand? Art Sci 21:1–4
Gstraunthaler G (2003) Alternatives to the use of fetal bovine serum: serum-free cell culture. ALTEX 20:275–281
Gstraunthaler G, Lindl T (2013) Zell- und Gewebekultur, 7th edn. Spektrum Springer Verlag, Heidelberg
Hodgson J (1991) Checking the sources: the serum supply secret. Nat Biotechnol 9:1320–1324
Hodgson J (1993) Fetal bovine serum revisited. Nat Biotechnol 11:49–53
Hodgson J (1995) To treat or not to treat: that is the question for serum. Nat Biotechnol 13:333–343
Jochems CE, van der Valk JBF, Stafleu FR, Baumans V (2002) The use of fetal bovine serum: ethical and scientific problem? ATLA 30:219–227
Nielsen O (1995) Changing serum’s mind-set. Nat Biotechnol 13:626
Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS (2011) The human serum metabolome. PLoS ONE 6:e16957
Rauch C, Feifel E, Amann E-M, Spötl HP, Schennach H, Pfaller W, Gstraunthaler G (2011) Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. ALTEX 28:305–316
Shailer C, Corrin K (1999) Serum supply: policies and controls operating in New Zealand. Dev Biol Stand 99:71–77
van der Valk J, Mellor D, Brands R, Fischer R, Gruber F, Gstraunthaler G, Hellebrekers L, Hyllner J, Jonker FH, Prieto P, Thalen M, Baumans V (2004) The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicol In Vitro 18:1–12
van der Valk J, Brunner D, De Smet K, Fex Svenningsen Å, Honegger P, Knudsen LE, Lindl T, Noraberg J, Price A, Scarino ML, Gstraunthaler G (2010) Optimization of chemically defined cell culture media—replacing fetal bovine serum in mammalian in vitro methods. Toxicol In Vitro 24:1053–1063
Wessmann SJ, Levings RL (1999) Benefits and risks due to animal serum used in cell culture production. Dev Biol Stand 99:3–8
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gstraunthaler, G., Lindl, T. & van der Valk, J. A plea to reduce or replace fetal bovine serum in cell culture media. Cytotechnology 65, 791–793 (2013). https://doi.org/10.1007/s10616-013-9633-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10616-013-9633-8